Treats major depressive disorder (MDD). ANDA 211603, held by Aurobindo Pharma Ltd. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 211603 (Doxepin Hydrochloride), held by Aurobindo Pharma Ltd, was first approved by FDA on Mar 27, 2019, with 0 approved supplements and 0 published complete response letters.
Doxepin hydrochloride capsules are indicated for the treatment of major depressive disorder (MDD) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2019 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 10MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 25MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 50MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 75MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 100MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters